BiotechTube
DRG International

DRG International

Princeton, United States· Est.
drg-international.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DRG International is a well-established, revenue-generating diagnostics company specializing in immunoassay development, manufacturing, and distribution. Its core offerings include ELISA kits for areas like autoimmune diseases, cancer, cardiac markers, and infectious diseases, alongside the DRG:HYBRiD-XL automated analyzer and distribution of CHROMagar media. Acquired by BioCheck, Inc. in 2021, the company leverages ISO 13485:2016 and MDSAP certifications to serve a broad international market through a direct and distributor network. Its strategy focuses on providing accessible, high-quality diagnostic tools to enable earlier treatment intervention.

Autoimmune DiseasesOncologyCardiologyInfectious DiseasesEndocrinologyFertility

Technology Platform

Immunoassay (ELISA) development and manufacturing; DRG:HYBRiD-XL automated analyzer for immunoassays and clinical chemistry; Distribution of chromogenic culture media (CHROMagar).

Opportunities

Growth in demand for specialized biomarkers (e.g., Hepcidin, Sclerostin) and automated, consolidated testing in mid-size labs via the HYBRiD-XL platform.
Significant geographic expansion potential in emerging markets using existing MDSAP and FDA certifications.
The trend toward non-invasive sampling creates an opportunity for its salivary ELISA assays.

Risk Factors

Faces intense competition from large, diversified diagnostics corporations with greater resources.
Operations are heavily dependent on maintaining complex global regulatory certifications (ISO, MDSAP, FDA).
Core ELISA technology could face long-term disruption from emerging diagnostic platforms like molecular testing.

Competitive Landscape

Operates in the highly competitive global immunoassay market, competing against giants like Abbott, Roche, Siemens Healthineers, and Danaher. Differentiates through niche biomarker focus, the HYBRiD-XL automated system, and a broad international distributor network. Also competes with other specialty ELISA manufacturers and laboratory equipment suppliers.

More companies in Diagnostics & Precision Medicine →More companies in United States →